Reuters logo
a year ago
BRIEF-Enanta Pharmaceuticals announces AbbVie's investigational HCV regimen receives U.S. FDA breakthrough therapy designation
September 30, 2016 / 12:52 PM / a year ago

BRIEF-Enanta Pharmaceuticals announces AbbVie's investigational HCV regimen receives U.S. FDA breakthrough therapy designation

Sept 30 (Reuters) - Enanta Pharmaceuticals Inc

* Enanta Pharmaceuticals announces AbbVie's investigational HCV regimen receives U.S. FDA breakthrough therapy designation

* According to FDA,BTD is intended to expedite development,review of an investigational therapy for serious condition Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below